Filing Details
- Accession Number:
- 0001628280-22-027125
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-10-26 20:01:36
- Reporting Period:
- 2022-10-24
- Accepted Time:
- 2022-10-26 20:01:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1894562 | Prime Medicine Inc. | PRME | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1219039 | Keith Crandell | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1229592 | Steven Gillis | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1569248 | Kristina Burow | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1757011 | Arch Venture Fund X, L.p. | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1757017 | Arch Venture Fund X Overage, L.p. | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1768905 | Arch Venture Partners X Overage, L.p. | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1769012 | Arch Venture Partners X, Llc | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No | |
| 1782583 | Arch Venture Partners X, L.p. | 8755 West Higgins Road, Suite 1025 Chicago IL 60631 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-10-24 | 5,728,297 | $0.00 | 5,728,297 | No | 4 | C | Indirect | By ARCH Venture Fund X, L.P. |
| Common Stock | Acquisiton | 2022-10-24 | 5,728,297 | $0.00 | 5,728,297 | No | 4 | C | Indirect | By ARCH Venture Fund X Overage, L.P. |
| Common Stock | Acquisiton | 2022-10-24 | 400,000 | $17.00 | 6,128,297 | No | 4 | P | Indirect | By ARCH Venture Fund X, L.P. |
| Common Stock | Acquisiton | 2022-10-24 | 400,000 | $17.00 | 6,128,297 | No | 4 | P | Indirect | By ARCH Venture Fund X Overage, L.P. |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | By ARCH Venture Fund X, L.P. |
| No | 4 | C | Indirect | By ARCH Venture Fund X Overage, L.P. |
| No | 4 | P | Indirect | By ARCH Venture Fund X, L.P. |
| No | 4 | P | Indirect | By ARCH Venture Fund X Overage, L.P. |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Convertible Preferred Stock | Disposition | 2022-10-24 | 16,666,667 | $0.00 | 5,361,122 | $0.00 |
| Common Stock | Series A Convertible Preferred Stock | Disposition | 2022-10-24 | 16,666,664 | $0.00 | 5,361,122 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2022-10-24 | 1,141,474 | $0.00 | 367,175 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2022-10-24 | 1,141,474 | $0.00 | 367,175 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date.
- Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X.
- ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose.
- Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage.
- Reflects shares purchased by ARCH X in the Issuer's initial public offering.
- Reflects shares purchased by ARCH X Overage in the Issuer's initial public offering.
Billionaire Hedge Funds
